Investors just paid about $4,000 per wrist for a $199-a-year band. Read the arithmetic.

WHOOP, the fitness-band company that received an FDA warning letter over a blood-pressure feature last July, has raised $575 million at a valuation of $10.1 billion, led by Collaborative Fund. The investor list includes Abbott, the Mayo Clinic, two Gulf sovereign funds and a roster of athletes. The company reports more than 2.5 million members, a basic membership of $149 for the first year and $199 after, plans to hire 600 people, and an intention to go public within one to two years. This is not an April Fools' post, though the arithmetic reads like one. Ten billion dollars divided by 2.5 million members is about $4,000 per wrist — twenty years of the $199 membership, paid up front by investors who expect to be repaid by something the band does not yet sell.

What $4,000 a wrist has to buy. Not sleep scores. A valuation like this prices in services that do not exist yet — the company describes AI models that flag early warning signs of serious health events — and two of the new investors tell you where: a diagnostics manufacturer and a hospital system. The path from a strain score to a medical claim runs through the FDA, which told this company in July that a blood-pressure gauge was on the wrong side of the line; Apple crossed that line in September with a cleared, deliberately modest hypertension flag. The money raised today is, in large part, the cost of crossing it properly. Whether the band's data can support cleared medical features is the open question, and $575 million is the bet that it can.

Ben’s take

This is the Oura playbook at larger scale: an installed base, a subscription, and a valuation that forces the product to become medical. I have sat in the rooms where the plan is drawn, and it always has the same shape — the band is the acquisition channel; the margin is in what you sell to a worried wearer next. A hospital system on the cap table is the tell. For the wearer, the question is unchanged since July: which of the numbers on your wrist could change a prescription, and who validated it?

Loree’s take

A clinic investing in a consumer band is not a clinical endorsement, and patients will read it as one. What the band does well — notice when you are run down — is useful. What the investment implies it will do — see serious illness coming — is a claim that needs trials, clearances and a clinician on the other end. Until then, a green recovery score is a weather report. I still want you to bring the cuff.

Why it matters to a recovering optimizer. The sleep and recovery you are tracking are two of the five fundamentals, and the band can help you notice them. The valuation is a different thing: a promise to investors that you will worry more, pay more and be sold more. You can keep the first and decline the second. Nothing in the fundamentals costs $4,000 a wrist.